With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation by 40% so far this week.

Shares of Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) have gained $19.82 to $69.02 since Friday's close, adding about

Read the full 566 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers